NAD+ IV infusions are among the most-searched longevity treatments and among the least studied — no published RCT has tested intravenous NAD+ against a validated aging or health outcome.
NAD+ IV therapy — direct intravenous infusion of nicotinamide adenine dinucleotide, bypassing oral absorption entirely — has become a common longevity-clinic offering, marketed on the premise that IV delivery achieves NAD+ tissue levels oral precursors (NMN, NR) cannot reach. This is a plausible pharmacokinetic argument that has not itself been directly tested or confirmed in a published human comparative trial.
No published RCT has tested IV NAD+ against a validated efficacy endpoint — cognitive function, physical performance, or any aging biomarker used elsewhere in the longevity literature. What exists is small, largely uncontrolled case-series data, primarily from addiction-recovery and chronic-fatigue clinical contexts unrelated to longevity.
The published literature on IV NAD+ skews heavily toward safety and tolerability rather than efficacy. Commonly reported acute effects during infusion include chest tightness, flushing, nausea, and abdominal cramping, generally described as dose- and infusion-rate-dependent and self-limiting when the infusion is slowed. No systematic long-term safety data exists for repeated NAD+ infusions over months or years, the pattern in which it is often marketed for ongoing longevity use.
By contrast, oral NAD+ precursors — NMN and NR — have actual published human RCTs, albeit still Emerging-tier evidence limited to surrogate endpoints (insulin sensitivity for NMN, aortic stiffness for NR). This means oral precursors, despite the theoretical bioavailability disadvantage IV marketing cites, currently have more human trial evidence behind them than IV NAD+ itself does — a counterintuitive but evidence-based comparison worth making explicit.
IV NAD+ therapy's evidence base currently consists of acute safety and tolerability observations, not efficacy data against any aging-relevant outcome, and long-term repeated-use safety data does not exist. Oral NAD+ precursors, despite a theoretical bioavailability disadvantage, currently have more actual human RCT evidence than IV NAD+ does.
This information is provided for educational reference only and does not constitute medical advice or a treatment recommendation.